A Multicenter, Randomized, Double-blind, Placebo-controlled 3-period Complete Cross-over Study to Assess the Bronchodilator Effects and Safety of Glycopyrronium Bromide (NVA237) (25 ug and 50 ug o.d.) in Asthma Patients.
Phase of Trial: Phase II/III
Latest Information Update: 18 Jan 2019
At a glance
- Drugs Glycopyrrolate (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 15 Feb 2018 Status changed from active, no longer recruiting to completed.
- 31 Jan 2018 The study has been completed in Belgium (2017-12-29).
- 28 Jan 2018 The study has been completed in Lithunia.